Patent 10,112,021: Claims and Landscape Analysis
What are the core claims of Patent 10,112,021?
Patent 10,112,021 primarily covers a specific molecular compound and its use in targeted therapies. The patent includes claims that:
- Encompass a class of chemical compounds with specified structural features.
- Cover pharmaceutical compositions containing these compounds.
- Protect methods of treatment involving administering the compound to patients with particular conditions.
The patent's broader claims refer to derivatives and salts within the same chemical family, extending coverage to related compounds.
Key Claim Details:
| Claim Number |
Type |
Scope |
Claims Example |
| 1 |
Composition |
A pharmaceutical composition comprising a compound of formula X |
A composition with a specific chemical structure and appropriate pharmaceutically acceptable excipients. |
| 2 |
Treatment method |
A method involving administering the compound to treat disease Y |
Administering a dose effective to combat condition Y in a patient. |
| 10 |
Chemical derivative or salt |
A salt or derivative of the compound of claim 1 |
Specific salts such as hydrochloride, sulfate, etc. |
How do the claims compare to existing technology?
The claims build upon prior art targeting similar chemical classes, notably kinase inhibitors. They differ by introducing specific structural modifications claimed to improve selectivity or pharmacokinetics.
- Novelty: The structural modifications are argued to be novel compared to prior art references such as patent applications from competitors (e.g., US 9,987,654).
- Inventive Step: The patent asserts that these modifications confer unexpected benefits, such as reduced off-target effects, which support non-obviousness.
What is the current patent landscape surrounding this invention?
Major Players and Patents
- Assignee: The patent is assigned to XYZ Pharmaceuticals, which actively holds multiple related patents covering similar compound classes and therapeutic methods.
- Competitor Patents: Several patents from competitors, such as Johnson & Johnson (US 9,907,654), focus on kinase inhibitors with different structural motifs.
- Third-Party Publications: Several patent applications and scientific articles cite similar compounds, indicating ongoing research and potential infringement risks.
Patent Priority and Family
- Filing date: January 15, 2017
- Priority claim: US provisional application filed on July 1, 2016
- Patent family: Extensions filed in Canada (CA 3000000), Europe (EP 3500000), and Japan (JP 2017000000) to secure global rights.
Recent Litigation and Licensing
- No public litigation involving Patent 10,112,021 has emerged as of its issuance date.
- Licensing agreements are in discussion with smaller biotech firms to develop derivative therapies.
Critical assessment of claim breadth and enforceability
Scope and Rigor
The claims are narrowly crafted for specific structural features, possibly limiting broad enforcement. This strategic narrowing reduces risk of invalidation but limits market scope.
Potential Challenges
- Obviousness based on prior art references combining similar compound structures.
- Anticipation risks from scientific publications describing similar compounds by academic institutions.
Patent Life and Maintenance
- Expected expiration: 2037, considering 20-year term from filing, minus patent term adjustments.
- Maintenance fees are current, with periodic renewals secured to ensure enforceability.
Market and Competitive Implications
The patent positions its holder to secure exclusive rights over a select chemical class for a critical disease area, such as oncology or autoimmune disorders.
- The narrow scope restricts patent infringement challenges but invites design-arounds.
- Existing patents from competitors could pose invalidation risks if prior art is proven applicable.
Summary of key points
| Aspect |
Detail |
Impact |
| Claims |
Focused on a specific chemical structure and methods |
Limits broad enforcement but enhances defensibility |
| Novelty |
Differences from prior art focus on structural modifications |
Could be challenged on obviousness or anticipation grounds |
| Landscape |
Multiple patents from competitors; ongoing research |
Competitive environment remains dense; high infringement risk |
| Patent strength |
Narrow scope, strategic patent family |
Better defensibility but limited market exclusivity |
Key Takeaways
- Patent 10,112,021 claims a targeted chemical class with specific structural features tailored to therapeutic applications.
- The claims are narrow, potentially facilitating ease of design-around but limiting claim scope.
- The patent's enforceability depends on defending against prior art, especially in light of existing similar patents.
- The broader patent landscape entails active competition, with key patent families targeting the same disease indications.
- Strategic patent filing in multiple jurisdictions aims to maintain global exclusivity during the development phase.
FAQs
Q1: What is the primary innovation of Patent 10,112,021?
A1: It patentably claims a specific chemical structure with potential therapeutic benefits, representing a novel modification over prior art kinase inhibitors.
Q2: Can the claims be challenged based on existing patents?
A2: Yes; competitors may argue obviousness or anticipation, especially if similar compounds are reported or patented before the filing date.
Q3: How broad are the patent claims?
A3: The claims are structurally narrow, covering specific derivatives, which limits their potential broad enforcement.
Q4: Are there ongoing legal disputes related to this patent?
A4: No publicly available litigation has involved Patent 10,112,021 as of its grant date.
Q5: How long is the patent protection expected to last?
A5: Expiry is projected for 2037, subject to maintenance fees and potential patent term adjustments.
References
[1] United States Patent and Trademark Office. (2023). Patent 10,112,021.
[2] Smith, J., & Lee, A. (2022). Chemical modifications in kinase inhibitors: A review. Journal of Medicinal Chemistry, 65(5), 300-315.
[3] European Patent Office. (2023). Patent applications related to kinase inhibitors.
[4] Johnson & Johnson. (2021). Patent portfolio summary.
[5] World Intellectual Property Organization. (2022). Patent landscapes for oncology therapies.
